MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2020.08.029

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2020

Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.

Eggermont Alexander M M, Bellomo Domenico, Arias-Mejias Suzette M, Quattrocchi Enrica, Sominidi-Damodaran Sindhuja, Bridges Alina G, Lehman Julia S, Hieken Tina J, Jakub James W, Murphree Dennis H, Pittelkow Mark R, Sluzevich Jason C, Cappel Mark A, Bagaria Sanjay P, Perniciaro Charles, Tjien-Fooh Félicia J, Rentroia-Pacheco Barbara, Wever Renske, van Vliet Martin H, Dwarkasing Jvalini, Meves Alexander

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Patients with stage I/IIA cutaneous melanoma (CM) are currently not eligible for adjuvant therapies despite uncertainty in relapse risk. Here, we studied the ability of a recently developed model which combines clinicopathologic and gene expression variables (CP-GEP) to identify stage I/IIA melanoma patients who have a high risk for disease relapse.

PATIENTS AND

METHODS

Archival specimens from a cohort of 837 consecutive primary CMs were used for assessing the prognostic performance of CP-GEP. The CP-GEP model combines Breslow thickness and patient age, with the expression of eight genes in the primary tumour. Our specific patient group, represented by 580 stage I/IIA patients, was stratified based on their risk of relapse: CP-GEP High Risk and CP-GEP Low Risk. The main clinical end-point of this study was five-year relapse-free survival (RFS).

RESULTS

Within the stage I/IIA melanoma group, CP-GEP identified a high-risk patient group (47% of total stage I/IIA patients) which had a considerably worse five-year RFS than the low-risk patient group; 74% (95% confidence interval [CI]: 67%-80%) versus 89% (95% CI: 84%-93%); hazard ratio [HR] = 2.98 (95% CI: 1.78-4.98); P < 0.0001. Of patients in the high-risk group, those who relapsed were most likely to do so within the first 3 years.

CONCLUSION

The CP-GEP model can be used to identify stage I/IIA patients who have a high risk for disease relapse. These patients may benefit from adjuvant therapy.

Для цитирования: Eggermont Alexander M M, Bellomo Domenico, Arias-Mejias Suzette M, Quattrocchi Enrica, Sominidi-Damodaran Sindhuja, Bridges Alina G, Lehman Julia S, Hieken Tina J, Jakub James W, Murphree Dennis H, Pittelkow Mark R, Sluzevich Jason C, Cappel Mark A, Bagaria Sanjay P, Perniciaro Charles, Tjien-Fooh Félicia J, Rentroia-Pacheco Barbara, Wever Renske, van Vliet Martin H, Dwarkasing Jvalini, Meves Alexander. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.. European journal of cancer (Oxford, England : 1990). 2020. DOI: 10.1016/j.ejca.2020.08.029.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.